Download PDF
Diabetes aktuell 2020; 18(03): 108-113
DOI: 10.1055/a-1152-2125
Schwerpunkt
© Georg Thieme Verlag Stuttgart · New York

Kardiovaskuläre Effekte von GLP-1-Rezeptoragonisten

Florian Kahles
1   Klinik für Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum Aachen
,
Michael Lehrke
1   Klinik für Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum Aachen
› Author Affiliations
Further Information

Publication History

Publication Date:
15 May 2020 (online)

Also available at
    Permissions and Reprints

ZUSAMMENFASSUNG

GLP-1-Rezeptoragonisten reduzieren die Häufigkeit kardiovaskulärer Ereignisse bei Patienten mit Diabetes. Dies wird über atheroprotektive Mechanismen vermittelt, wobei bisher unklar ist, inwieweit direkte immunmodulierende und antientzündliche Eigenschaften der Substanzen hierfür verantwortlich sind. GLP-1-Rezeptoragonisten werden für Patienten mit Diabetes und einem hohen kardiovaskulären Risiko unabhängig vom HbA1c-Wert als Erstlinientherapie empfohlen, was einem Paradigmenwechsel in der Diabetestherapie entspricht. In diesem Beitrag werden die kardiovaskulären Outcomestudien zu den GLP-1-Rezeptoragonisten vorgestellt und die möglichen Wirkmechanismen in den verschiedenen Organsystemen diskutiert.

 

  • Literatur

  • 1 International Diabetes Federation IDF Diabetes Atlas 8th Edition. Im Internet https://www.idf.org/e-library/epidemiology-research/diabetes-atlas/134-idf-diabetes-atlas-8th-edition.html Stand: 10.02.2020
    Google Scholar
  • 2 Rao Kondapally Seshasai S, Kaptoge S, Thompson A. et al Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011; 364: 829-841 doi:10.1056/NEJMoa1008862
    CrossrefPubMedGoogle Scholar
  • 3 Holman RR, Sourij H, Califf RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet 2014; 383: 2008-2017 doi:10.1016/S0140-6736(14)60794-7
    CrossrefPubMedGoogle Scholar
  • 4 Hess K, Marx N, Lehrke M. Cardiovascular disease and diabetes: the vulnerable patient. Eur Heart J Suppl 2012; 14: B4-B13 doi:10.1093/eurheartj/sus002
    CrossrefGoogle Scholar
  • 5 Rawshani A, Rawshani A, Franzén S. et al Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2018; 379: 633-644 doi:10.1056/NEJMoa1800256
    CrossrefPubMedGoogle Scholar
  • 6 Gaede P, Lund-Andersen H, Parving HH. et al Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-591 doi:10.1056/NEJMoa0706245
    CrossrefPubMedGoogle Scholar
  • 7 ADVANCE Collaborative Group Patel A, MacMahon S. et al Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572 doi:10.1056/NEJMoa0802987
    CrossrefPubMedGoogle Scholar
  • 8 Duckworth W, Abraira C, Moritz T. et al Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139 doi:10.1056/NEJMoa0808431
    CrossrefPubMedGoogle Scholar
  • 9 ACCORD Study Group Gerstein HC, Miller ME. et al Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011; 364: 818-828 doi:10.1056/NEJMoa1006524
    CrossrefPubMedGoogle Scholar
  • 10 Meinert CL, Knatterud GL, Prout TE. et al A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970; 19 Suppl 789-830
    Google Scholar
  • 11 Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471 doi:10.1056/NEJMoa072761
    CrossrefPubMedGoogle Scholar
  • 12 U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) Guidance for industry: Diabetes mellitus — evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008
    PubMedGoogle Scholar
  • 13 Cefalu WT, Kaul S, Gerstein HC. et al Cardiovascular outcomes trials in type 2 diabetes: Where do we go from here? Reflections from a Diabetes Care Editors’ Expert Forum. Diabetes Care 2018; 41: 14-31 doi:10.2337/dci17-0057
    CrossrefPubMedGoogle Scholar
  • 14 Scirica BM, Bhatt DL, Braunwald E. et al Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-1326 doi:10.1056/NEJMoa1307684
    CrossrefPubMedGoogle Scholar
  • 15 White WB, Cannon CP, Heller SR. et al Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327-1335 doi:10.1056/NEJMoa1305889
    CrossrefPubMedGoogle Scholar
  • 16 Green JB, Bethel MA, Armstrong PW. et al Effect of stagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373: 232-242 doi:10.1056/NEJMoa1501352
    CrossrefPubMedGoogle Scholar
  • 17 Pfeffer MA, Claggett B, Diaz R. et al Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015; 373: 2247-2257 doi:10.1056/NEJMoa1509225
    CrossrefPubMedGoogle Scholar
  • 18 Holman RR, Bethel MA, Mentz RJ. et al Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017; 377: 1228-1239 doi:10.1056/NEJMoa1612917
    CrossrefPubMedGoogle Scholar
  • 19 Zinman B, Inzucchi SE, Lachin JM. et al Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME). Cardiovasc Diabetol 2014; 13: 102 doi:10.1186/1475-2840-13-102
    CrossrefPubMedGoogle Scholar
  • 20 Wiviott SD, Raz I, Bonaca MP. et al Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380: 347-357 doi:10.1056/NEJMoa1812389
    CrossrefPubMedGoogle Scholar
  • 21 Perkovic V, Jardine MJ, Neal B. et al Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380: 2295-2306 doi:10.1056/NEJMoa1811744
    CrossrefPubMedGoogle Scholar
  • 22 Neal B, Perkovic V, Mahaffey KW. et al Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644-657 doi:10.1056/NEJMoa1611925
    CrossrefPubMedGoogle Scholar
  • 23 Marso SP, Daniels GH, Brown-Frandsen K. et al Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311-322 doi:10.1056/NEJMoa1603827
    CrossrefPubMedGoogle Scholar
  • 24 Marso SP, Bain SC, Consoli A. et al Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375: 1834-1844 doi:10.1056/NEJMoa1607141
    CrossrefPubMedGoogle Scholar
  • 25 Hernandez AF, Green JB, Janmohamed S. et al Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 2018; 392: 1519-1529 doi:10.1016/S0140-6736(18)32261-X
    CrossrefPubMedGoogle Scholar
  • 26 Gerstein HC, Colhoun HM, Dagenais GR. et al Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019; 394: 121-130 doi:10.1016/S0140-6736(19)31149-3
    CrossrefPubMedGoogle Scholar
  • 27 Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 2013; 17: 819-837 doi:10.1016/j.cmet.2013.04.008
    CrossrefPubMedGoogle Scholar
  • 28 Eng J, Kleinman WA, Singh L. et al Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992; 267: 7402-7405
    CrossrefPubMedGoogle Scholar
  • 29 Mann JFE, Ørsted DD, Brown-Frandsen K. et al Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 2017; 377: 839-848 doi:10.1056/NEJMoa1616011
    CrossrefPubMedGoogle Scholar
  • 30 Gerstein HC, Colhoun HM, Dagenais GR. et al Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet 2019; 394: 131-138 doi:10.1016/S0140-6736(19)31150-X
    CrossrefPubMedGoogle Scholar
  • 31 Verma S, Poulter NR, Bhatt DL. et al Effects of liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke. Circulation 2018; 138: 2884-2894 doi:10.1161/CIRCULATIONAHA.118.034516
    CrossrefPubMedGoogle Scholar
  • 32 Verma S, Bhatt DL, Bain SC. et al Effect of liraglutide on cardiovascular events in patients with type 2 diabetes mellitus and polyvascular disease: Results of the LEADER trial. Circulation 2018; 137: 2179-2183 doi:10.1161/CIRCULATIONAHA.118.033898
    CrossrefPubMedGoogle Scholar
  • 33 Marx N, Libby P. Cardiovascular benefits of GLP-1 receptor agonism: Is inflammation a key?. JACC Basic Transl Sci 2018; 3: 858-860 doi:10.1016/j.jacbts.2018.11.008
    PubMedGoogle Scholar
  • 34 Htike ZZ, Zaccardi F, Papamargaritis D. et al Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab 2017; 19: 524-536 doi:10.1111/dom.12849
    CrossrefPubMedGoogle Scholar
  • 35 Gentilella R, Pechtner V, Corcos A. et al Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?. Diabetes Metab Res Rev 2019; 35: e3070 doi:10.1002/dmrr.3070
    CrossrefPubMedGoogle Scholar
  • 36 Brown E, Wilding JPH, Barber TM. et al Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities. Obes Rev 2019; 20: 816-828 doi:10.1111/obr.12841
    CrossrefPubMedGoogle Scholar
  • 37 Maloney A, Rosenstock J, Fonseca V. A model-based meta-analysis of 24 antihyperglycemic drugs for type 2 diabetes: Comparison of treatment effects at therapeutic doses. Clin Pharmacol Ther 2019; 105: 1213-1223 doi:10.1002/cpt.1307
    Google Scholar
  • 38 Seghieri M, Christensen AS, Andersen A. et al Future perspectives on GLP-1 receptor agonists and GLP-1/glucagon receptor co-agonists in the treatment of NAFLD. Front Endocrinol (Lausanne) 2018; 9: 649 doi:10.3389/fendo.2018.00649
    CrossrefPubMedGoogle Scholar
  • 39 Armstrong MJ, Gaunt P, Aithal GP. et al Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 2016; 387: 679-690 doi:10.1016/S0140-6736(15)00803-X
    CrossrefPubMedGoogle Scholar
  • 40 Rizzo M, Nikolic D, Patti AM. et al GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms. Biochim Biophys Acta Mol Basis Dis 2018; 1864: 2814-2821 doi:10.1016/j.bbadis.2018.05.012
    CrossrefPubMedGoogle Scholar
  • 41 Song X, Jia H, Jiang Y. et al Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis. Sci Rep 2015; 5: 10202 doi:10.1038/srep10202
    CrossrefPubMedGoogle Scholar
  • 42 Almutairi M, Al Batran R, Ussher JR. Glucagon-like peptide-1 receptor action in the vasculature. Peptides 2019; 111: 26-32 doi:10.1016/j.peptides.2018.09.002
    CrossrefPubMedGoogle Scholar
  • 43 Tashiro Y, Sato K, Watanabe T. et al A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis. Peptides 2014; 54: 19-26 doi:10.1016/j.peptides.2013.12.015
    CrossrefPubMedGoogle Scholar
  • 44 Gaspari T, Welungoda I, Widdop RE. et al The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE(-/-) mouse model. Diab Vasc Dis Res 2013; 10: 353-360 doi:10.1177/1479164113481817
    CrossrefPubMedGoogle Scholar
  • 45 Verma S, Leiter LA, Mazer CD. et al Liraglutide reduces cardiovascular events and mortality in type 2 diabetes mellitus independently of baseline low-density lipoprotein cholesterol levels and statin use. Circulation 2018; 138: 1605-1607 doi:10.1161/CIRCULATIONAHA.118.036862
    CrossrefPubMedGoogle Scholar
  • 46 Zelniker TA, Wiviott SD, Raz I. et al Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation 2019; 139: 2022-2031 doi:10.1161/CIRCULATIONAHA.118.038868
    CrossrefPubMedGoogle Scholar
  • 47 Tuttle KR, McKinney TD, Davidson JA. et al Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials. Diabetes Obes Metab 2017; 19: 436-441 doi:10.1111/dom.12816
    CrossrefPubMedGoogle Scholar
  • 48 Thomas MC. The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes. Diabetes Metab 2017; 43 (Suppl. 01) 2S20-2S27 doi:10.1016/S1262-3636(17)30069-1
    CrossrefPubMedGoogle Scholar
  • 49 Nauck MA, Meier JJ, Cavender MA. et al Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation 2017; 136: 849-870 doi:10.1161/CIRCULATIONAHA.117.028136
    CrossrefPubMedGoogle Scholar
  • 50 Lønborg J, Vejlstrup N, Kelbæk H. et al Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 2012; 33: 1491-1499 doi:10.1093/eurheartj/ehr309
    CrossrefPubMedGoogle Scholar
  • 51 Nauck MA, Tornøe K, Rasmussen S. et al Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial. Diab Vasc Dis Res 2018; 15: 465-468 doi:10.1177/1479164118783935
    CrossrefPubMedGoogle Scholar
  • 52 Margulies KB, Hernandez AF, Redfield MM. et al Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: A randomized clinical trial. JAMA 2016; 316: 500-508 doi:10.1001/jama.2016.10260
    CrossrefPubMedGoogle Scholar
  • 53 Lepore JJ, Olson E, Demopoulos L. et al Effects of the novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure and reduced ejection fraction. JACC Heart Fail 2016; 4: 559-566 doi:10.1016/j.jchf.2016.01.008
    CrossrefPubMedGoogle Scholar
  • 54 Consoli A, Formoso G, Baldassarre MPA. et al A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment. Expert Opin Drug Saf 2018; 17: 293-302 doi:10.1080/14740338.2018.1428305
    CrossrefPubMedGoogle Scholar
  • 55 Husain M, Birkenfeld AL, Donsmark M. et al Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2019; 381: 841-851 doi:10.1056/NEJMoa1901118
    CrossrefPubMedGoogle Scholar